Biogen Inc. (NASDAQ:BIIB) Shares Sold by JNBA Financial Advisors

02 Jul 2025, 06:02 by Renee Jackson · The Cerbat Gem

JNBA Financial Advisors cut its holdings in Biogen Inc. (NASDAQ:BIIB – Free Report) by 27.7% in the 1st quarter, HoldingsChannel reports. The fund owned 626 shares of the biotechnology company’s stock after selling 240 shares during the period. JNBA Financial Advisors’ holdings in Biogen were worth $86,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of BIIB. Amundi grew its position in shares of Biogen by 35.6% in the fourth quarter. Amundi now owns 1,216,990 shares of the biotechnology company’s stock valued at $183,461,000 after purchasing an additional 319,478 shares during the period. Integrated Quantitative Investments LLC acquired a new stake in Biogen in the 4th quarter worth about $407,000. Daiwa Securities Group Inc. grew its holdings in Biogen by 17.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 37,221 shares of the biotechnology company’s stock valued at $5,692,000 after buying an additional 5,627 shares during the period. State of Michigan Retirement System increased its stake in shares of Biogen by 59.9% during the 4th quarter. State of Michigan Retirement System now owns 63,503 shares of the biotechnology company’s stock valued at $9,711,000 after acquiring an additional 23,800 shares during the last quarter. Finally, APG Asset Management N.V. lifted its holdings in shares of Biogen by 346.1% during the 4th quarter. APG Asset Management N.V. now owns 105,446 shares of the biotechnology company’s stock worth $15,572,000 after acquiring an additional 81,811 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Stock Up 3.6%

BIIB stock opened at $130.07 on Wednesday. The firm has a fifty day moving average price of $126.09 and a two-hundred day moving average price of $134.82. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.44 and a quick ratio of 1.01. Biogen Inc. has a 1-year low of $110.04 and a 1-year high of $238.00. The firm has a market cap of $19.06 billion, a price-to-earnings ratio of 12.84, a PEG ratio of 1.00 and a beta of 0.14.

Biogen (NASDAQ:BIIB – Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share for the quarter, missing the consensus estimate of $3.26 by ($0.24). Biogen had a return on equity of 14.03% and a net margin of 15.07%. The business had revenue of $2.43 billion for the quarter, compared to analyst estimates of $2.25 billion. During the same quarter last year, the company earned $3.67 EPS. Biogen’s revenue was up 6.2% compared to the same quarter last year. Research analysts predict that Biogen Inc. will post 15.83 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on BIIB. Hsbc Global Res downgraded shares of Biogen from a “strong-buy” rating to a “hold” rating in a report on Monday, April 28th. Canaccord Genuity Group lowered their price objective on shares of Biogen from $265.00 to $220.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. Wedbush reaffirmed a “neutral” rating and issued a $121.00 target price on shares of Biogen in a research report on Thursday, June 12th. Truist Financial reduced their target price on Biogen from $210.00 to $199.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Finally, JPMorgan Chase & Co. dropped their price target on Biogen from $185.00 to $175.00 and set a “neutral” rating for the company in a research note on Monday, May 5th. Twenty equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Biogen has a consensus rating of “Hold” and a consensus target price of $188.48.

Read Our Latest Stock Report on Biogen

Biogen Company Profile

(Free Report)

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

Biogen Inc. (NASDAQ:BIIB) Shares Sold by JNBA Financial Advisors

Biogen Stock Up 3.6%

Wall Street Analyst Weigh In

Biogen Company Profile

Recommended Stories